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What was known before: 
Some uveal melanomas can be treated by enucleation or proton beam radiotherapy (PBR). To 
make effective decisions about which treatment to use, clinicians and patients need to understand 
potential adverse outcomes of each. Adverse clinical effects of each procedure are widely 
understood, but it is not known how patients experience these effects.  
 
 
What this study adds: 
Enucleation was associated with transient functional problems on tasks requiring binocular vision. 
PBR was associated with greater impairments of central and peripheral vision, and reading 
difficulties. No differences in adverse effects were reported for driving, ocular irritation, headaches, 
appearance concerns or worries about cancer recurrence. Findings can help patients and clinicians 
to make better informed decisions between enucleation and PBR  
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Background: Uveal melanomas affect 2-8 per million Europeans each year. Approximately 
35%, are treated by enucleation. Proton beam radiotherapy (PBR) can be an eye-conserving 
alternative to enucleation for patients who wish to retain the eye. Both treatments have 
adverse effects, and it is difficult for clinicians and patients to make fully informed choices 
between them because the relative effects of enucleation and PBR on patient-reported 
outcomes are unknown.  
Methods: We compared differential effects of enucleation and PBR on patient reported 
outcomes on the European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire- Ophthalmological module (EORTC QLQ- OPT30) in a consecutive 
sample of 115 treated patients approximately 6, 12 and 24 months after diagnosis. Pre-
treatment demographic variables, unrelated health problems, vision in the fellow eye, tumour 
characteristics and prognosis for metastatic disease were statistically controlled.  
Results: Patients treated by enucleation experienced greater functional problems at 6 months, 
which abated at 12 and 24 months (P=.020). PBR patients reported greater impairments of 
central and peripheral vision (P=.009) and reading difficulties (P=.002) over 24 months. 
Treatment modality did not influence difficulty in driving (P=.694), ocular irritation 
(P=.281), headaches (P=.640), appearance concerns (P=.187) or worry about recurrence 
(P=.899).  
Conclusions: When making treatment decisions, it is important that patients and clinicians 
consider long-standing difficulties of visual impairment associated with PBR and temporary 
6-month difficulties in activities related to depth perception associated with enucleation.   
 
 







Uveal melanoma (UM) is a rare cancer of the eye that affects 2-8 individuals per million 2 
Caucasian people per year in Europe, depending on ocular pigmentation.1 UM treatments aim 3 
to preserve the eye with useful vision. Plaque radiotherapy is a preferred treatment in many 4 
centres2 but not recommended in some centres where tumours are large or close to the optic 5 
disc. In these cases, enucleation can be considered. 3,4  6 
Enucleation is performed in approximately 35% of patients.5   Adverse outcomes are 7 
loss of binocular vision, potential socket-related complications and phantom symptoms such 8 
as visual sensations.6 PBR is sometimes an alternative to enucleation when patients wish to 9 
retain the eye. PBR preserves the eye but carries risks of neovascular glaucoma, radiation 10 
retinopathy, papillopathy, retinal detachment, local tumour recurrence7,8 and collateral 11 
damage to extraocular structures such as eye lids, lacrimal gland and tear ducts.9 12 
Decisions of whether to preserve the eye or not are not always clinically clear cut. In 13 
these cases, careful consideration of the consequences of treatments are necessary for 14 
effective treatment decisions.4 Patients may prefer to retain the eye, although doing so 15 
confers clinical disadvantage, or prefer enucleation in the absence of decisive clinical 16 
need.4,10 To make informed decisions, clinicians and patients need to understand potential 17 
consequences of enucleation and PBR.  18 
Objective probabilities of adverse side effects, local and distant recurrence and overall 19 
survival are known 3,11,12 and patients are routinely informed of these.4  To our knowledge, no 20 
study has examined how enucleation and PBR influence patients’ experiences of adverse 21 
treatment outcomes. Loss of binocular vision after enucleation causes a range of problems 22 
associated with distance perception, whilst prostheses can cause irritation, discomfort, pain 23 




and appearance dissatisfaction.13,14  Adverse patient-reported outcomes of PBR can include 24 
progressive visual impairments, linked to known central and peripheral visual loss and the 25 
presence of unwanted visual sensations, and cause discomfort due to tissue damage to 26 
extraocular structures.9 These outcomes are associated with the likelihood of developing long 27 
term clinically-relevant anxiety and depression in UM patients.15 28 
It is unknown whether enucleation and PBR differentially affect worry about cancer 29 
recurrence (WREC). In our unit, that treats between 200 to 250 new patients with uveal 30 
melanoma per annum, some patients worry about local recurrence and wish to reduce this 31 
worry through enucleation.4 Studies in other cancers confirm that patients sometimes request 32 
radical surgeries to remove organs because they fear local cancer recurrence.16 WREC is 33 
linked to clinically relevant anxiety15 thus clinicians may regard reducing patients’ fears of 34 
recurrence as a valid consideration for treatment choice.17 However, there is as yet no 35 
evidence that enucleation reduces fear to a greater extent than PBR in UM patients.   36 
Our aim was to identify any differential effects of treatment modality (enucleation 37 
versus PBR) on patient-reported outcomes of ocular irritation, visual impairment, headaches, 38 
appearance concerns, functional problems, reading and driving problems, and WREC. We 39 
compared treatment modalities approximately 6, 12 and 24 months after diagnosis.a As 40 
treatment decisions are influenced by patient and tumour characteristics, we statistically 41 
adjusted age, gender, presence or absence of unrelated health problems, visual acuity in the 42 
fellow eye at diagnosis, tumour size, and prognosis for metastatic disease. Poor prognosis for 43 
metastatic disease was defined by the presence of monosomy 3 (loss of one copy of 44 
chromosome 3) in tumour cells. 45 
 46 
                                                            
a Some data used in this report are the same of those used by Damato et al 27. The Damato study focusses on a 
broader question pertaining to trajectories of patient reported outcomes over time after radiotherapy, 
whereas this paper addresses a specific clinical question pertaining to adverse effects of enucleation compared 
to PBR for large tumours. 





This study was approved as a clinical audit by the Health Research Authority North West – 48 
Liverpool Central Ethics Committee (03/06/072/A) and was conducted in accordance with 49 
the Declaration of Helsinki.  50 
Design 51 
Prospective design with patient-reported outcome measures taken at 6, 12 and 24 months 52 
after diagnosis, in non-randomised consecutive samples of enucleated or PBR patients with 53 
clinical and demographic variables statistically controlled. As plaque radiotherapy was not 54 
considered to be clinically viable due to tumour characteristics or position, these patients 55 
were excluded so as not to dilute the analysis. Data were taken from a larger project, thus no 56 
power analyses were made for this specific investigation.18 57 
Participants 58 
Informed consent was sought from a consecutive series of adult patients treated at the 59 
Liverpool Ocular Oncology Centre (LOOC) for posterior uveal melanoma (i.e., choroid and 60 
ciliary body) between April 1st 2008 and December 31st 2011. We excluded non-enucleation 61 
or non PBR treatments and patients with tumours that involved the iris. The final sample 62 
consisted of patients who provided data at each of the three follow-ups. 63 
Diagnosis and treatment of uveal melanoma was based on clinical and tumour 64 
characteristics, as described by Damato and Heimann. 4 Where tumours were relatively small 65 
or medium sized (thickness <6mm diameter <18mm) or not close to the optic disc, plaque 66 
radiotherapy was the preferred treatment. Enucleation was considered for larger tumour size 67 
and PBR for tumours with optic disc involvement or larger tumours (thickness >6mm) where 68 
patients wished to keep the eye and the tumour diameter was <18mm. Patient preferences for 69 
or against particular procedures were considered in treatment selection.  70 
Data collected  71 




At the time of diagnosis, patients were asked if they were willing to participate in an audit to 72 
examine long-term patient-reported outcomes of treatment. All patients who gave written 73 
consent were posted the self-report questionnaire with enclosed postage-paid envelopes 74 
addressed to the audit team 6, 12 and 24 months following diagnosis. 75 
Sociodemographic and clinical characteristics of the sample were collected from 76 
patients’ clinical records. These were age, gender, patient-identified unrelated health 77 
problems, relationship status, employment status, whether the right or left eye was affected, 78 
vision in the fellow eye at diagnosis as logMAR scores, tumour origin (choroid or ciliary 79 
body), tumour size (ultrasound height and largest basal diameter) and treatment modality. 80 
Prognostication was based on chromosome 3 status as the primary determinant of life 81 
expectancy12, 19 and was categorized as: monosomy 3, disomy 3 (i.e., normal maternal and 82 
paternal copies of chromosome 3) and unknown (comprising patients who did not wish to be 83 
tested, tumours were small, and those whose genetic test failed). For patients undergoing 84 
PBR, prognostic biopsies were usually performed on the last day of treatment. 85 
Following treatment, symptoms and functional problems were measured using the 86 
European Organisation for Research and Treatment for Cancer Ophthalmic Oncology Quality 87 
of Life questionnaire module (EORTC QLQ- OPT30) 20 designed specifically for UM 88 
patients and validated in UM samples. 21 Subscales specific to enucleation or PBR were not 89 
used. Details of the subscale items are shown in table 1. 90 
Statistical analysis 91 
Sample Retention: Multivariate logistic regression was used to test whether baseline age, sex, 92 
health problems, chromosome-3 status, logMAR scores for the fellow eye, tumour thickness, 93 
and largest basal diameter and 6-month EORTC QLQ- OPT30 scores predicted retention in 94 
the sample at 12 and 24 months.  95 




Outcomes for each treatment modality: Data were normally distributed and showed 96 
homogeneity of variance. Firstly, mixed–model analyses of variance (MANOVAs) were used 97 
to predict EORTC QLQ- OPT30 scores at 6, 12 and 24 months. Enucleation versus PBR 98 
treatment was a two-group predictor variable. To prevent confounding by pre-treatment 99 
differences between treatment groups, these analyses were repeated with statistical 100 
adjustment using age, sex, health problems, chromosome 3 status, logMAR scores for the 101 
fellow eye, tumour thickness, and largest basal diameter as covariates. Chromosome 3 status 102 
was coded into two binomial variables; the first denoting monosomy 3 or not (including those 103 
with disomy 3 and those whose chromosome-3 status was unknown), the second denoting 104 
disomy 3 or not (monosomy 3 and unknown). 105 
Results 106 
Sample Description and Retention Analysis  107 
360 patients were approached to participate. Of these, 194 returned questionnaires at 6 108 
months, 155 at 12 months and 132 at 24 months. 115 returned questionnaires at all three 109 
time-points and were included (59.3% retention). Sixty six patients were treated by 110 
enucleation and 49 treated by PBR. Demographic and clinical characteristics for each 111 
treatment group are presented in Table 2. Monosomy 3 was more prevalent in enucleated 112 
patients. The logistic regression predicting 24 month retention from 6-month study variables 113 
was not significant (χ2=15.23, Nagelkerke R2=1.06, df=14, p=.294), showing no bias in 114 
retention. 115 
 116 
Outcomes by Treatment Modality 117 




Estimated marginal means and results of unadjusted and adjusted significance tests for 118 
outcome variables at 6, 12 and 24 months after diagnosis are shown in Table 3.b Enucleation 119 
was associated with greater ocular irritation, appearance concerns, and functional problems, 120 
with treatment differences in functional problems significantly reducing over time. 121 
Unadjusted means show PBR to be associated with greater reading difficulties scores.  122 
Statistical Adjustment changed statistical significance in some analyses. Enucleated 123 
patients experienced more functional problems at 6 months, but these reduced linearly over  124 
12 and 24 months (F=4.00, df=2 p=.020) with Bonferroni post-hoc tests showing a significant 125 
reduction between 6 and 24 month observations but not between adjacent observations. PBR 126 
patients experienced more visual impairment and had more difficulty in reading over all time 127 
points than enucleated patients. No differences between treatment modalities were apparent at 128 
any time point for ocular irritation, headaches, appearance concerns, driving difficulties, or 129 
WREC.  130 
Discussion 131 
To our knowledge, this study is the first to document differential effects of enucleation and 132 
PBR on patient-reported outcomes. Enucleation was initially associated with greater 133 
functional problems which lessened after six months, whilst patients treated by PBR reported 134 
greater visual impairment and reading difficulties than those treated by enucleation. 135 
Treatment modality did not influence difficulty in driving, ocular irritation, headaches, 136 
appearance concerns, or WREC. Our findings will allow clinicians to better understand how 137 
patients are likely to be affected by consequences of enucleation relative to PBR, and to 138 
inform patients accordingly. 139 
Findings are consistent with known clinical effects of enucleation and PBR. 140 
Enucleation eliminates binocular vision, creating difficulties with depth perception. 22 The 141 
                                                            
b We examined whether treatment modality effects were moderated or accentuated by covariates. We did not 
observe clear patterns of moderation or accentuation of treatment effects. 




functional problems scale is weighted toward tasks requiring depth perception, such as 142 
judging distances, pouring drinks and using stairs. Thus, it is unsurprising that enucleated 143 
patients reported greater functional problems. Relative functional improvement over 24 144 
months suggests that patients either developed compensatory strategies, such as using 145 
alternative cues to judge distance, or changed daily routines, such as avoiding distance 146 
perception tasks. 23,24 After PBR, patients experienced visual impairments and reading 147 
difficulties over 24 months. This is consistent with reports of lower visual acuity and greater 148 
visual interference.3,8,9 149 
Treatment modality had little relative effect on ocular irritation, headaches or driving 150 
difficulties. It is not feasible to compare our patients to those who had neither enucleation nor 151 
PBR (due to large initial differences in patient and tumour characteristics). Thus, we do not 152 
know whether equivalence between treatment modalities occurs because neither treatment 153 
has adverse effects, or that treatments adversely affect outcomes in different but 154 
approximately equivalent ways. Ocular irritation and headaches may also arise from 155 
equivalent adverse effects; enucleation can cause socket damage14 and PBR can cause 156 
damage to extraocular structures, such as eyelids, canaliculi and the lacrimal gland 9. 157 
Enucleation may adversely affect driving due to loss of depth perception, and PBR due to 158 
diminished visual acuity. It is unclear as to whether treatment modalities did not differentially 159 
affect driving or whether patients did experience driving difficulties after one or the other 160 
treatments and simply stopped driving.   161 
It might be expected that enucleation would increase concerns about appearance, as 162 
dissatisfaction with prostheses is relatively common.13 This indeed was the case before 163 
statistical adjustment, but no differences in appearance concerns were observed after 164 
adjustment. Thus, treatment differences are probably attributable to pre-treatment differences 165 
between treatment groups, and unlikely to be a consequence of enucleation. The equivalence 166 




of appearance concerns between enucleation and PBR may reflect either recent advances in 167 
the development of implants and prostheses 14,25 or a generally low concern about appearance 168 
in our sample of older patients. 24 169 
Some patients may opt for enucleation to avoid worry about recurrence. Unlike breast 170 
cancer, where women achieve reductions of fear and worry after mastectomy, 26 enucleation 171 
did not differentially reduce worry compared to PBR. Enucleated patients were more likely to 172 
have monosomy 3, although evidence suggests that this is not necessarily associated with 173 
worry about recurrence.15 Enucleation can reduce the small probability of local cancer 174 
recurrence, but we have no evidence that it reduces patients’ subjective worry about 175 
recurrence.   176 
This study has several limitations. Due to initial disparity in patient and tumour 177 
characteristics, it was unfeasible to compare our findings with patient groups who had neither 178 
enucleation nor PBR. Thus, we cannot comment on how each procedure affects patients in 179 
absolute terms. Second, patients could not be randomised to treatment modality. Although we 180 
used a series of statistical adjustments, we cannot exclude the possibility of confounding. 181 
Nonetheless, findings are not confounded by pre-treatment group differences in demographic 182 
variables, unrelated illnesses, tumour size or chromosome-3 status, which were statistically 183 
controlled. We used a relatively small sample and had 53.9% initial recruitment and 59.3% 184 
retention, although retention analysis showed retention to be unbiased. Last, questionnaires 185 
were self-administered without supervision, which might lead to greater error than 186 
professionally-administered scales.   187 
Findings of this study can help clinicians and patients to make informed decisions 188 
between enucleation and PBR. Firstly, enucleation can lead to greater functional difficulties 189 
associated with depth perception tasks, although this difference between the treatments 190 
seemed to abate after 12 months. PBR on the other hand is more likely to lead to patient 191 




reported difficulties with visual impairments, experienced as loss of vision or visual problems 192 
in the treated eye affecting vision in the fellow eye. This is problematic for reading. 193 
Secondly, patients can be informed that enucleation will reduce the possibility of local 194 
recurrence in the affected eye, but it is unlikely to help them to reduce worry about 195 
recurrence.  Finally, choice of treatment modality is unlikely to cause greater difficulties 196 
associated with ocular irritation, appearance or driving.197 
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